Recent Software Case Gives Important Lessons For Biotech
Oct 10th, 2016 by Nicholas Vincent | News | Recent News & Articles |
On September 13, the Federal Circuit held that a series of ordered combination of steps related to lip-synch software did not constitute an abstract idea, and was subsequently patent eligible under §101 (McRO, Inc. v. Bandai Namco Games America). This decision reversed and remanded an earlier decision issued by the United States District Court for the Central District of California in McRO, Inc. v. Sony Computer Entertainment America, LLC. This case, which was followed closely by the IT community, also has important, positive implications for the patent eligibility of biotech inventions.